PREMONITION: Multiple Sclerosis Prediction and Monitoring of Progression Study
Study Details
Study Description
Brief Summary
Multiple sclerosis (MS) is a auto-immune disease that is mostly characterized by acute clinical relapses and/or focal inflammation in the central nervous system (CNS) followed by recovery. Yet, a significant part of the patients also experience a progressive decline in function. This progressive phase usually has an insidious onset causing a delay for diagnosis and adjusted therapies. There are plenty of clinical assessments available to measure walking speed, cognition, sleep,.... . But these assessments are merely a snapshot of the patient 's symptoms. By monitoring these parameters at home, real life data can be provided to capture subclinical signs of progression. The goal of this study is to detect a digital biomarker for progressive MS at an earlier stage next to validating wearables by comparing them to golden standard measurements such a polysomnography or gait analysis in a specialized lab.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Background:
Multiple sclerosis (MS) is the most common cause of non-traumatic neurological disability in young adults leading to an important personal and socio-economic burden. From a pathophysiological point of view MS is considered to be an autoimmune disease in which the immune system mistakenly attacks the central nervous system (CNS). MS is usually devided into three clinical phases. Most people with MS experience sudden relapses followed by a remitting periode (RRMS). Fot this type of MS, the therapeutic landscape has evolved extensively over the last decade. Unfortunately, a significant part of the patients still experience progressive decline in function despite not experiencing discrete clinical relapses. The progressive MS phenotype can be divided in two subtypes known as SPMS and primary progressive MS (PPMS) dependent on preceding RRMS or not. A variety of clinical measures has enabled us to compose a valid follow-up of the disease course, yet they do not evaluate outpatient or long-term monitoring and they also lack sensitivity for early detection of disability progression. Up-to-date, there is no clear consensus on how to diagnose SPMS and it remains difficult to define when a patient enters the progressive phase as the diagnosis is usually made retrospectively. Implementing digital biomarkers would potentially provide us with a more realistic and more sensitive view of the progressive evolution in different spheres of functioning. This also counts for autonomic dysfunction and sleeping disorders, where no standardized monitoring is available for MS. Using wearables to capture the digital biomarkers could fill the gap of knowledge in evaluating, monitoring and predicting disability progression in MS. to this day there is no precise biomarker or composite tool that can differentiate the MS phenotypes or help us initiate/adjust therapy earlier on in progression. Introducing wearable's that could collect basic clinical parameters on a day-to-day basis would potentially give researchers a more realistic and more sensitive insight of the general course of the disease.
Rationale:
Evolution in machine learning enables unbiased detection of biomarkers encoded in different biosignal modalities. The ability to track MS disease-related physiological and behavioral signals over longer periods of time on an outpatient basis serves the unmet need of early diagnosis and adequate monitoring of (relapse independent) disease progression. This has major clinical implications since biomonitoring could be a critical tool for MS care practitioners in patient-centered multidisciplinary care.
Study design:
This is an open-label, monocentric diagnostic study where the investigators will test the feasibility and validity (as compared to golden standard measures) of wearables, provided by Byteflies, in adequate extended outpatient evaluation and monitoring of PwMS. The investigators will further evaluate how these biosignals correlate with conventional outcome measures at their primary visit to evaluate the prognostic potential of wearable monitoring
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Healthy volunteer 20 Healthy volunteers required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots 15 Non-MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots |
Device: Bytelfies kit - sensor dot
Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.
GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.
PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand
Other Names:
|
| Experimental: People with MS 20 patients with MS required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots 15 MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots |
Device: Bytelfies kit - sensor dot
Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.
GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.
PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To validate outpatient gait analysis using sensor dots, with regards to the golden standard [1 single study visit which takes approximately 2 hours]
Participants (healthy volunteers and MS patients) will perform a gait analysis on the Gait Real-time Analysis Interactive Lab (GRAIL), which is considered to be the golden standard, whilst simultaneously wearing the byteflies sensor dots. By comparing data from the GRAIL (golden standard) with the data from the sensor dots, which uses gyroscopic and accelerometric data, we aim to be able to validate the following gait parameters for outpatient use: Stride length Stride time Stance (%) Total double support (%) Single support (%) Walking speed Cadence
- To validate outpatient polysomnography using sensor dots, with regards to the golden standard [Healthy participants: 1 study visit which encompasses an overnight stay in the hospital. Duration: about 15 hours. PwMS: 1 overnight stay, followed by outpatient sleep analysis for 2 nights. Total duration: 3 days]
Participants (non-MS and MS patients)with an indication for polysomnography(PSG) will undergo a standard PSG with a simultaneous Byteflies sensor dot registration for comparising. Patients with MS will undergo an additional outpatient sleep analysis with the byteflieskit during 2 consecutive nights. The following parameters will monitored by the byteflies sensor dots. Electrooculography (EOG): for eye movements. Electroencephalografphy (EEG): EEG signals to define the sleeping stages Oxygenation Chest wall expansion: calculated with accelerometric and gyroscopic monitoring Electrocardiography(ECG): ECG signals to measure heart rate and heart rate variability Leg movement: calculated with accelerometric and gyroscopic monitoring
Secondary Outcome Measures
- Skin-device contact safety [GAIT: 2 hours; Sleep (healthy volunteers): 15 hours; Sleep (PwMS): 3 days]
A clinical evaluation of subjects for possible local reactions at the skin-device contact sites will be performed.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Relapsing Remitting (RR) or Primary Progressive (PPMS) MS as defined by 2017 Mc Donald criteria, or Secondary Progressive (SPMS) according to Lorscheider criteria AND having an EDSS ≤ 6.5
-
Healthy control
-
Non-MS Patient with an indication for polysomnography
-
Age 18-60 years inclusive
Exclusion Criteria:
-
Patients who were prescribed 4-aminopyridin during the last 30 days.
-
Patients with severe cardiac, pneumological, neurological, hematological, immunological, infectious, rheumatoid, endocrinological, gastro-intestinal, urological comorbidity that may interfere with outcome measures as determined by the investigators.
-
Confirmed clinical relapses or new lesions on MRI during the last six months
-
Known allergy to electrodes used as part of the study protocol
-
Having an implanted device, such as (but not limited to) a pacemaker, cardioverter defibrillator (ICD), and/or neural stimulation device.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital Ghent | Ghent | Oost-Vlaanderen | Belgium | 9000 |
Sponsors and Collaborators
- University Hospital, Ghent
- University Ghent
- Byteflies
Investigators
- Principal Investigator: Guy Laureys, MD, PhD, University Hospital, Ghent
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BC-07811
- CIV-BE-20-09-034669